A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity

Virology

Volumn 410, Issue 1, 2011, Pages 96-106

  Ma, Jian ^a,b   Shi, Nan ^a   Jiang, Cheng Gang ^a   Lin, Yue Zhi ^a   Wang, Xue Feng ^a   Wang, Shuai ^a   Lv, Xiao Ling ^a   Zhao, Li Ping ^a   Shao, Yi Ming ^c   Kong, Xian Gang ^a   Zhou, Jian Hua ^a   Shen, Rong Xian ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NORTHEAST FORESTRY UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Antigen diversity; EIAV; Protection; Proviral derivative; Vaccine

Indexed keywords

EQUINE INFECTIOUS ANEMIA VIRUS VACCINE; GLYCOPROTEIN GP 90; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA; EQUINE INFECTIOUS ANEMIA VIRUS; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; IMMUNOGENETICS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROVIRUS; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CLONING, MOLECULAR; EQUINE INFECTIOUS ANEMIA; FEMALE; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MALE; PROVIRUSES; VACCINES, ATTENUATED; VIRAL LOAD; VIRAL VACCINES; VIRULENCE;

EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 78650777492     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.032     Document Type: Article

References (47)

1. Bakhanashvili M., Hizi A. Fidelity of DNA synthesis exhibited in vitro by the reverse transcriptase of the lentivirus equine infectious anemia virus. Biochemistry 1993, 32:7559-7567.
2. Ball J.M., Rushlow K.E., Issel C.J., Montelaro R.C. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J. Virol. 1992, 66:732-742.
3. Barouch D.H., Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med. 2010, 61:153-167.
4. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., Buckler-White A., Igarashi T., Theodore T., Byrum R., Kemp C., Montefiori D.C., Martin M.A. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 2001, 75:2224-2234.
5. Cohen J. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor. Science 2004, 304:1437.
6. Cook R.F., Berger S.L., Rushlow K.E., McManus J.M., Cook S.J., Harrold S., Raabe M.L., Montelaro R.C., Issel C.J. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein. J. Virol. 1995, 69:1493-1499.
7. Cook R.F., Leroux C., Cook S.J., Berger S.L., Lichtenstein D.L., Ghabrial N.N., Montelaro R.C., Issel C.J. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J. Virol. 1998, 72:1383-1393.
8. Cook R.F., Cook S.J., Berger S.L., Leroux C., Ghabrial N.N., Gantz M., Bolin P.S., Mousel M.R., Montelaro R.C., Issel C.J. Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides. Virology 2003, 313:588-603.
9. Cook R.F., Cook S.J., Bolin P.S., Howe L.J., Zhou W., Montelaro R.C., Issel C.J. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies. Vet. Microbiol. 2005, 108:23-37.
10. Craigo J.K., Li F., Steckbeck J.D., Durkin S., Howe L., Cook S.J., Issel C., Montelaro R.C. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J. Virol. 2005, 79:2666-2677.
11. Craigo J.K., Sturgeon T.J., Cook S.J., Issel C.J., Leroux C., Montelaro R.C. Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 2006, 344:340-353.
12. Craigo J.K., Durkin S., Sturgeon T.J., Tagmyer T., Cook S.J., Issel C.J., Montelaro R.C. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 2007, 25:834-845.
13. Glenn A.A., Novembre F.J. A single amino acid change in gp41 is linked to the macrophage-only replication phenotype of a molecular clone of simian immunodeficiency virus derived from the brain of a macaque with neuropathogenic infection. Virology 2004, 325:297-307.
14. Hammond S.A., Cook S.J., Falo L.D., Issel C.J., Montelaro R.C. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 1999, 254:37-49.
15. Harrold S.M., Cook S.J., Cook R.F., Rushlow K.E., Issel C.J., Montelaro R.C. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J. Virol. 2000, 74:3112-3121.
16. He X., Shao Y.M., Xue F., Fan X.J., R.X.S. Construction of infectious chimeric clones of equine infectious anemia virus (EIAV). Chin. J. Virol. 2003, 19128-19132.
17. Howe L., Leroux C., Issel C.J., Montelaro R.C. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J. Virol. 2002, 76:10588-10597.
18. Hurwitz J.L., Slobod K.S., Lockey T.D., Wang S., Chou T.H., Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Curr. Drug Targets Infect. Disord. 2005, 5:143-156.
19. Hurwitz J.L., Zhan X., Brown S.A., Bonsignori M., Stambas J., Lockey T.D., Sealy R., Surman S., Freiden P., Jones B., Martin L., Blanchard J., Slobod K.S. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front. Biosci. 2008, 13:609-620.
20. Issel C.J., Horohov D.W., Lea D.F., Adams W.V., Hagius S.D., McManus J.M., Allison A.C., Montelaro R.C. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 1992, 66:3398-3408.
21. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., Sata T., Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J. Virol. 2005, 79:5996-6004.
22. Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 2009, 4:408-417.
23. Leroux C., Craigo J.K., Issel C.J., Montelaro R.C. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J. Virol. 2001, 75:4570-4583.
24. Leroux C., Cadore J.L., Montelaro R.C. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?. Vet. Res. 2004, 35:485-512.
25. Li F., Leroux C., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J. Virol. 2000, 74:573-579.
26. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., Montelaro R.C. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J. Virol. 2003, 77:7244-7253.
27. Liang H., He X., Shen R.X., Shen T., Tong X., Ma Y., Xiang W.H., Zhang X.Y., Shao Y.M. Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV. Arch. Virol. 2006, 151:1387-1403.
28. Ma J., Jiang C., Lin Y., Wang X., Zhao L., Xiang W., Shao Y., Shen R., Kong X., Zhou J. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine. Arch. Virol. 2009, 154:867-873.
29. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
30. McGuire T.C., Fraser D.G., Mealey R.H. Cytotoxic T lymphocytes in protection against equine infectious anemia virus. Anim. Health Res. Rev. 2004, 5:271-276.
31. Montelaro R.C., Grund C., Raabe M., Woodson B., Cook R.F., Cook S., Issel C.J. Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. AIDS Res. Hum. Retroviruses 1996, 12:413-415.
32. Payne S.L., Fuller F.J. Virulence determinants of equine infectious anemia virus. Curr. HIV Res. 2010, 8:66-72.
33. Preston B.D., Poiesz B.J., Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
34. Ridgely S.L., Zhang B., McGuire T.C. Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge. Vaccine 2003, 21:491-506.
35. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
36. Ruprecht R.M. Live attenuated AIDS viruses as vaccines: promise or peril?. Immunol. Rev. 1999, 170:135-149.
37. Sealy R., Slobod K.S., Flynn P., Branum K., Surman S., Jones B., Freiden P., Lockey T., Howlett N., Hurwitz J.L. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int. Rev. Immunol. 2009, 28:49-68.
38. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., Koup R.A., Mascola J.R., Nabel G.J., Letvin N.L. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 2005, 79:2956-2963.
39. Shen R.X., Wang Z. Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine. EIAV: A National Review of Policies, Programs, and Future Objectives 1985, American Quarter Horse Association, Amarillo, Tex.
40. Shen R.X., Xu Z.D., He X.S., Zhang S.X. Study on immunological methods of equine infectious anemia. China Agric. Sci. 1979, 1-15.
41. Shen, R.X., Wang, Z.Y., Dong, J.P., 2001. Fetal donkey dermal cells adapted attenuated vaccine of equine infectious anemia virus and its culture method. (Chinese patent No. 01123620). In China (ed.).
42. Shen T., Liang H., Tong X., Fan X., He X., Ma Y., Xiang W., Shen R., Zhang X., Shao Y. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 2006, 24:738-749.
43. Srivastava I.K., Ulmer J.B., Barnett S.W. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccin. 2004, 3:S33-S52.
44. Tumas D.B., Hines M.T., Perryman L.E., Davis W.C., McGuire T.C. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J. Gen. Virol. 1994, 75(Pt 5):959-968.
45. Whitney J.B., Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 2004, 17:17-26.
46. Zhan X., Martin L.N., Slobod K.S., Coleclough C., Lockey T.D., Brown S.A., Stambas J., Bonsignori M., Sealy R.E., Blanchard J.L., Hurwitz J.L. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005, 23:5306-5320.
47. Zheng Y.H., Sentsui H., Nakaya T., Kono Y., Ikuta K. In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain. J. Virol. 1997, 71:5031-5039.